Oriola-KD makes changes to management team

Henry Fogels adds acting director general of wholesale business in Russia to his duties

Henry Fogels, general director of Oriola-KD's Pharmaceutical Retail business in Russia (OOO Vitim) has been nominated, in addition to his current duties, to the position of acting general director of Oriola-KD's Pharmaceutical Wholesale business in Russia.

Fogels will continue as a member of Oriola-KD's Group Management Team, being responsible for Oriola-KD's businesses in Russia.

Fogels has replaced Vladimir Knyazev, who left the Espoo, Finland-based company this month.

You may also like

Manufacturing

Oriola-KD to sell healthcare trade business to Mediq

Dutch firm to acquire Oriola-KD businesses across Scandinavia and Europe
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Autoinjector platforms: optimising device selection and unlocking manufacturing efficiency for injectable pipelines

Owing to ageing populations, the increased prevalence of chronic disease and additional pressure on global healthcare systems, among other factors, the market for drug delivery devices for self-administration (autoinjectors) is growing
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

OMass and Genentech to develop and commercialise therapies for inflammatory bowel disease

The collaboration leverages OMass’ Odyssion platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Subscribe now